Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

PURPOSE: No standard of care therapy exists for patients with metastatic uveal melanoma who are not HLA-A2:01 positive. The phase 1b, open-label CLEVER study (NCT03408587) evaluated V937 in combination with ipilimumab in patients with uveal melanoma. METHODS: Adults with advanced uveal melanoma and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutzky, Jose, Sullivan, Ryan J., Cohen, Justine V., Ren, Yixin, Li, Anlong, Haq, Rizwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356892/
https://www.ncbi.nlm.nih.gov/pubmed/36651961
http://dx.doi.org/10.1007/s00432-022-04510-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356892/
https://www.ncbi.nlm.nih.gov/pubmed/36651961
http://dx.doi.org/10.1007/s00432-022-04510-3

Ejemplares similares